冠状动脉血栓形成的病理生理学及经皮冠状动脉介入治疗期间血栓的不良后果。
Pathophysiology of coronary thrombus formation and adverse consequences of thrombus during PCI.
作者信息
Srikanth Sundararajan, Ambrose John A
机构信息
Interventional Cardiology Fellow, UCSF Fresno, CA, USA.
出版信息
Curr Cardiol Rev. 2012 Aug;8(3):168-76. doi: 10.2174/157340312803217247.
Abstract
Atherosclerosis is a systemic vascular pathology that is preceded by endothelial dysfunction. Vascular inflammation "fuels" atherosclerosis and creates the milieu for episodes of intravascular thromboses. Thrombotic events in the coronary vasculature may lead to asymptomatic progression of atherosclerosis or could manifest as acute coronary syndromes or even sudden cardiac death. Thrombus encountered in the setting of acute coronary syndromes has been correlated with acute complications during percutaneous coronary interventions such as no-reflow, acute coronary occlusion and long term complications such as stent thrombus. This article reviews the pathophysiology of coronary thrombogenesis and explores the complications associated with thrombus during coronary interventions.
摘要
动脉粥样硬化是一种全身性血管病变，其发生之前存在内皮功能障碍。血管炎症“助长”动脉粥样硬化，并为血管内血栓形成创造条件。冠状动脉系统中的血栓事件可能导致动脉粥样硬化的无症状进展，或表现为急性冠状动脉综合征甚至心源性猝死。急性冠状动脉综合征时出现的血栓与经皮冠状动脉介入治疗期间的急性并发症（如无复流、急性冠状动脉闭塞）以及长期并发症（如支架血栓形成）相关。本文综述了冠状动脉血栓形成的病理生理学，并探讨了冠状动脉介入治疗期间与血栓相关的并发症。
相似文献
1
Pathophysiology of coronary thrombus formation and adverse consequences of thrombus during PCI.
Curr Cardiol Rev. 2012 Aug;8(3):168-76. doi: 10.2174/157340312803217247.
2
Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature.
Curr Vasc Pharmacol. 2019;17(2):164-179. doi: 10.2174/1570161116666180101150956.
3
Plaque Composition and No-Reflow Phenomenon During Percutaneous Coronary Intervention of Low-Echoic Structures in Grayscale Intravascular Ultrasound.
Int Heart J. 2016 May 25;57(3):285-91. doi: 10.1536/ihj.15-373. Epub 2016 May 9.
4
The impact of initial and residual thrombus burden on the no-reflow phenomenon in patients with ST-segment elevation myocardial infarction.
Coron Artery Dis. 2015 May;26(3):245-53. doi: 10.1097/MCA.0000000000000197.
5
Predictive performance of dual modality of computed tomography angiography and intravascular ultrasound for no-reflow phenomenon after percutaneous coronary stenting in stable coronary artery disease.
Heart Vessels. 2018 Oct;33(10):1121-1128. doi: 10.1007/s00380-018-1160-2. Epub 2018 Apr 11.
6
The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
JACC Cardiovasc Interv. 2011 May;4(5):495-502. doi: 10.1016/j.jcin.2010.12.012.
7
The iatrogenic pathology of percutaneous interventions in coronary arteries.
Minerva Med. 2012 Dec;103(6):487-502.
8
Clinical significance of intracoronary thrombus aspirated during primary percutaneous intervention: An immunohistopathological study.
Cardiovasc Revasc Med. 2018 Apr;19(3 Pt A):241-246. doi: 10.1016/j.carrev.2017.09.009. Epub 2017 Sep 22.
9
A simple and rapid method for identification of lesions at high risk for the no-reflow phenomenon immediately before elective coronary stent implantation.
Heart Vessels. 2016 Dec;31(12):1904-1914. doi: 10.1007/s00380-016-0825-y. Epub 2016 Mar 2.
10
Thrombus age, clinical presentation, and reperfusion grade in myocardial infarction.
Cardiovasc Pathol. 2014 May-Jun;23(3):126-30. doi: 10.1016/j.carpath.2014.01.007. Epub 2014 Jan 23.
引用本文的文献
1
Multifunctional applications and research advances of low-molecular-weight heparin.
Front Pharmacol. 2025 May 21;16:1585762. doi: 10.3389/fphar.2025.1585762. eCollection 2025.
2
ANti-Thrombotic strAtegy for the management of nonocclusive thRombus with ST-segment elevation myocardial infarCtion in young pAtients - ANTARTICA study.
Indian Heart J. 2025 Jan-Feb;77(1):14-21. doi: 10.1016/j.ihj.2024.12.003. Epub 2024 Dec 20.
3
The association between HbA1c/C-peptide levels and short-term mortality in patients diagnosed with myocardial infarction.
Biomark Med. 2024 Aug 17;18(15-16):665-673. doi: 10.1080/17520363.2024.2380248. Epub 2024 Aug 5.
4
The effect of the systemic immune-inflammatory index on the no-reflow phenomenon in patients undergoing saphenous vein intervention.
Postepy Kardiol Interwencyjnej. 2024 Jun;20(2):148-156. doi: 10.5114/aic.2024.140259. Epub 2024 Jun 4.
5
The Role of Pan-Immune-Inflammation Value in Determining the Severity of Coronary Artery Disease in NSTEMI Patients.
J Clin Med. 2024 Feb 25;13(5):1295. doi: 10.3390/jcm13051295.
6
Natural products targeting inflammation-related metabolic disorders: A comprehensive review.
Heliyon. 2023 Jun 2;9(6):e16919. doi: 10.1016/j.heliyon.2023.e16919. eCollection 2023 Jun.
7
Recurrent Chest Pain Due to a Huge Left Main Aneurysm: A Case Report.
J Tehran Heart Cent. 2022 Jan;17(1):33-37. doi: 10.18502/jthc.v17i1.9324.
8
Cardiac Magnetic Resonance Shows Improved Outcomes in Patients with an ST-Segment Elevation Myocardial Infarction and a High Thrombus Burden Treated with Adjuvant Aspiration Thrombectomy.
J Clin Med. 2022 Aug 25;11(17):5000. doi: 10.3390/jcm11175000.
9
Association of stress induced hyperglycemia with angiographic findings and clinical outcomes in patients with ST-elevation myocardial infarction.
Cardiovasc Diabetol. 2022 Jul 26;21(1):140. doi: 10.1186/s12933-022-01578-6.
10
Predicting Cardiovascular Stent Complications Using Self-Reporting Biosensors for Noninvasive Detection of Disease.
Adv Sci (Weinh). 2022 May;9(15):e2105285. doi: 10.1002/advs.202105285. Epub 2022 Mar 24.
本文引用的文献
1
Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses.
Int J Cardiol. 2013 Jul 31;167(2):575-84. doi: 10.1016/j.ijcard.2012.01.080. Epub 2012 Feb 22.
2
Composition of coronary thrombus in acute myocardial infarction.
J Am Coll Cardiol. 2011 Mar 22;57(12):1359-67. doi: 10.1016/j.jacc.2010.09.077.
3
Coronary microembolization: from bedside to bench and back to bedside.
Circulation. 2009 Nov 3;120(18):1822-36. doi: 10.1161/CIRCULATIONAHA.109.888784.
4
Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation.
Arterioscler Thromb Vasc Biol. 2010 Jan;30(1):75-9. doi: 10.1161/ATVBAHA.109.195024. Epub 2009 Oct 8.
5
Frequency of elevated troponin I and diagnosis of acute myocardial infarction.
Am J Cardiol. 2009 Jul 1;104(1):9-13. doi: 10.1016/j.amjcard.2009.03.003. Epub 2009 May 4.
6
A comparison of 2 thrombus aspiration devices with histopathological analysis of retrieved material in patients presenting with ST-segment elevation myocardial infarction.
JACC Cardiovasc Interv. 2008 Jun;1(3):258-64. doi: 10.1016/j.jcin.2008.03.014.
7
Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction.
Eur Heart J. 2009 Apr;30(8):908-15. doi: 10.1093/eurheartj/ehp033. Epub 2009 Feb 18.
8
Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory.
Catheter Cardiovasc Interv. 2008 Dec 1;72(7):950-7. doi: 10.1002/ccd.21715.
9
Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.
J Am Coll Cardiol. 2008 Sep 30;52(14):1134-40. doi: 10.1016/j.jacc.2008.07.006.
10
Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study.
Lancet. 2008 Jun 7;371(9628):1915-20. doi: 10.1016/S0140-6736(08)60833-8.
Zotero 插件